NICE Crysvita decision revised after negotiations

X-Linked Hypophosphataemia treatment Crysvita (burosumab) is to be approved by NICE after the agency reversed its draft decision.

In its Evaluation Consultation Document of the drug (published in June 2018), NICE did not recommend the medicine, questioning its cost-effectiveness.

However in its Final Evaluation Document, which has now been published, NICE revised its decision and recommended the drug. This comes after the company negotiated a lower price via a patient access scheme (PAS) , which will result in the NHS getting a discount on the list price.

Positive NICE guidance (expected 24th October) means the drug will be made routinely available on the NHS in England. Crysvita is currently available within England under an Early Access arrangement.

Tagged with

Published 7. September 2018 in News, News UK